You are here:

rivaroxaban (Xarelto)

Advice

following a full submission:

rivaroxaban (Xarelto®) is accepted for use within NHS Scotland.

Indication under review: treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults.

Rivaroxaban was non-inferior to a regimen including a low molecular weight heparin and a vitamin K antagonist for the treatment of PE and the prevention of recurrence of DVT or PE.  Duration of treatment was 3, 6 or 12 months at the discretion of the treating physician.

Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.

Drug Details

Drug Name: rivaroxaban (Xarelto)
SMC Drug ID: 852/13
Manufacturer: Bayer plc/Bayer Schering Pharma
Indication: Treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 March 2013

Back